XOMA and XOMAO Related Headlines
Go Back- Ligand to acquire XOMA Royalty for $739 million in cash deal
- Ligand to Acquire XOMA Royalty, Further Accelerating Profit Growth and Strengthening Ligand’s Position as a Leading Biopharma Royalty Aggregator
- XOMA Royalty Declares Quarterly Preferred Stock Dividends
- XOMA Royalty Declares Quarterly Preferred Stock Dividends
- XOMA extends LAVA acquisition tender offer to October 17
- XOMA Royalty Extends Tender Offer to Acquire LAVA Therapeutics N.V.
- XOMA Royalty Declares Quarterly Preferred Stock Dividends
- XOMA Royalty Announces Closing of Tender Offer for Turnstone Biologics
- XOMA Royalty Declares Quarterly Preferred Stock Dividends
XOMA and XOMAO Related Press Releases
Go Back- Ligand to Acquire XOMA Royalty, Further Accelerating Profit Growth and Strengthening Ligand’s Position as a Leading Biopharma Royalty Aggregator
- XOMA Royalty Declares Quarterly Preferred Stock Dividends
- XOMA Royalty Declares Quarterly Preferred Stock Dividends
- XOMA Royalty Extends Tender Offer to Acquire LAVA Therapeutics N.V.
- XOMA Royalty Declares Quarterly Preferred Stock Dividends
- XOMA Royalty Announces Closing of Tender Offer for Turnstone Biologics
- XOMA Royalty Declares Quarterly Preferred Stock Dividends
